PDCD1 and metastatic melanoma: In 2012 nivolumab-a mAb against programmed cell death 1 (PD-1)-improved progression-free survival, overall survival, demonstrated an increased response rate and could achieve an up to 35% long term survival in patients with metastatic melanoma [52,53].